{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:36:38Z","timestamp":1789648598863,"version":"4.0.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12882-019-1263-8","type":"journal-article","created":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T10:06:06Z","timestamp":1551434766000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing"],"prefix":"10.1186","volume":"20","author":[{"given":"Matthias","family":"Diebold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4114-9560","authenticated-orcid":false,"given":"Andreas D.","family":"Kistler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,1]]},"reference":[{"issue":"3","key":"1263_CR1","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1097\/MNH.0000000000000317","volume":"26","author":"D Collister","year":"2017","unstructured":"Collister D, Rigatto C, Tangri N. Anemia management in chronic kidney disease and dialysis: a narrative review. Curr Opin Nephrol Hypertens. 2017;26(3):214\u20138.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"9","key":"1263_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJM199808273390903","volume":"339","author":"A Besarab","year":"1998","unstructured":"Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339(9):584\u201390.","journal-title":"N Engl J Med"},{"issue":"20","key":"1263_CR3","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa062276","volume":"355","author":"TB Drueke","year":"2006","unstructured":"Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071\u201384.","journal-title":"N Engl J Med"},{"issue":"21","key":"1263_CR4","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","volume":"361","author":"MA Pfeffer","year":"2009","unstructured":"Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019\u201332.","journal-title":"N Engl J Med"},{"issue":"20","key":"1263_CR5","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMoa065485","volume":"355","author":"AK Singh","year":"2006","unstructured":"Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085\u201398.","journal-title":"N Engl J Med"},{"key":"1263_CR6","doi-asserted-by":"crossref","unstructured":"Perez-Garcia R, Varas J, Cives A, Martin-Malo A, Aljama P, Ramos R, et al. Increased mortality in haemodialysis patients administered high doses of erythropoiesis-stimulating agents: a propensity score-matched analysis. Nephrol Dial Transplant. 2017.","DOI":"10.1093\/ndt\/gfx269"},{"issue":"Suppl 2","key":"1263_CR7","first-page":"279","volume":"2","author":"KDIGO Anaemia Work Group","year":"2012","unstructured":"KDIGO Anaemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. 2012;2(Suppl 2):279\u2013335.","journal-title":"Kidney Int"},{"issue":"1","key":"1263_CR8","first-page":"173","volume":"32","author":"WM Michels","year":"2017","unstructured":"Michels WM, Jaar BG, Ephraim PL, Liu Y, Miskulin DC, Tangri N, et al. Intravenous iron administration strategies and anemia management in hemodialysis patients. Nephrol Dial Transplant. 2017;32(1):173\u201381.","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1","key":"1263_CR9","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1111\/hdi.12560","volume":"21","author":"M Auerbach","year":"2017","unstructured":"Auerbach M, Macdougall I. The available intravenous iron formulations: history, efficacy, and toxicology. Hemodial Int. 2017;21(Suppl 1):S83\u201392.","journal-title":"Hemodial Int"},{"issue":"2","key":"1263_CR10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.semnephrol.2016.02.004","volume":"36","author":"R Pandey","year":"2016","unstructured":"Pandey R, Daloul R, Coyne DW. Iron treatment strategies in Dialysis-dependent CKD. Semin Nephrol. 2016;36(2):105\u201311.","journal-title":"Semin Nephrol"},{"issue":"6","key":"1263_CR11","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/ndt\/gft033","volume":"28","author":"F Locatelli","year":"2013","unstructured":"Locatelli F, B\u00e1r\u00e1ny P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, et al. Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European renal best practice position statement. Nephrol Dial Transplant. 2013;28(6):1346\u201359.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"1263_CR12","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1053\/j.ajkd.2013.06.008","volume":"62","author":"AS Kliger","year":"2013","unstructured":"Kliger AS, Foley RN, Goldfarb DS, Goldstein SL, Johansen K, Singh A, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for Anemia in CKD. Am J Kidney Dis. 2013;62(5):849\u201359.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"1263_CR13","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1053\/j.ajkd.2013.08.001","volume":"62","author":"LM Moist","year":"2013","unstructured":"Moist LM, Troyanov S, White CT, Wazny LD, Wilson JA, McFarlane P, et al. Canadian Society of Nephrology commentary on the 2012 KDIGO clinical practice guideline for Anemia in CKD. Am J Kidney Dis. 2013;62(5):860\u201373.","journal-title":"Am J Kidney Dis"},{"key":"1263_CR14","unstructured":"National Clinical Guideline C. National Institute for Health and Care Excellence: Clinical guidelines. Anaemia Management in Chronic Kidney Disease: partial update 2015. London: Royal College of Physicians (UK). National Clinical Guideline Centre.; 2015"},{"issue":"5","key":"1263_CR15","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1592\/phco.24.6.574.34750","volume":"24","author":"PA Seligman","year":"2004","unstructured":"Seligman PA, Dahl NV, Strobos J, Kimko HC, Schleicher RB, Jones M, et al. Single-dose pharmacokinetics of sodium ferric gluconate complex in iron-deficient subjects. Pharmacotherapy. 2004;24(5):574\u201383.","journal-title":"Pharmacotherapy."},{"issue":"6a","key":"1263_CR16","first-page":"362","volume":"60","author":"P Geisser","year":"2010","unstructured":"Geisser P, Banke-Bochita J. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia. Arzneimittel-Forschung. 2010;60(6a):362\u201372.","journal-title":"Arzneimittel-Forschung."},{"issue":"12","key":"1263_CR17","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1182\/blood.V90.12.4979","volume":"90","author":"TN Tran","year":"1997","unstructured":"Tran TN, Eubanks SK, Schaffer KJ, Zhou CY, Linder MC. Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron. Blood. 1997;90(12):4979\u201386.","journal-title":"Blood."},{"issue":"5","key":"1263_CR18","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1053\/j.ajkd.2016.04.018","volume":"68","author":"D Shepshelovich","year":"2016","unstructured":"Shepshelovich D, Rozen-Zvi B, Avni T, Gafter U, Gafter-Gvili A. Intravenous versus Oral Iron supplementation for the treatment of Anemia in CKD: an updated systematic review and meta-analysis. Am J Kidney Dis. 2016;68(5):677\u201390.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1263_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0272-6386(99)70103-4","volume":"34","author":"A Besarab","year":"1999","unstructured":"Besarab A, Kaiser JW. Frinak S. A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis. 1999;34(1):21\u20138.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"1263_CR20","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1053\/j.ajkd.2011.05.021","volume":"58","author":"K Shalansky","year":"2011","unstructured":"Shalansky K, Hanko J, Pudek M, Li G, Jastrzebski J. Iron indices after administration of sodium ferric gluconate complex in hemodialysis patients. Am J Kidney Dis. 2011;58(4):684\u20135.","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"1263_CR21","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1345\/aph.1Q614","volume":"46","author":"T Kapoian","year":"2012","unstructured":"Kapoian T, O'Mara NB, Carreon M, Gajary A, Rizkala A, Lefavour G, et al. Iron indices and intravenous ferumoxytol: time to steady-state. Ann Pharmacother. 2012;46(10):1308\u201314.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"1263_CR22","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1186\/s12882-017-0745-9","volume":"18","author":"BM Robinson","year":"2017","unstructured":"Robinson BM, Larkina M, Bieber B, Kleophas W, Li Y, Locatelli F, et al. Evaluating the effectiveness of IV iron dosing for anemia management in common clinical practice: results from the Dialysis outcomes and practice patterns study (DOPPS). BMC Nephrol. 2017;18(1):330.","journal-title":"BMC Nephrol"},{"issue":"Suppl 1","key":"1263_CR23","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/ckj\/sfx042","volume":"10","author":"JS Berns","year":"2017","unstructured":"Berns JS. Interpretation of the kidney disease: improving global outcomes guidelines for iron therapy: commentary and emerging evidence. Clin Kidney J. 2017;10(Suppl 1):i3\u20138.","journal-title":"Clin Kidney J"},{"issue":"8","key":"1263_CR24","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1093\/ndt\/gfq069","volume":"25","author":"A Covic","year":"2010","unstructured":"Covic A, Mircescu G. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-Centre, open-label, clinical study. Nephrol Dial Transplant. 2010;25(8):2722\u201330.","journal-title":"Nephrol Dial Transplant"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1263-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1263-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1263-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T19:09:41Z","timestamp":1582916981000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1263-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1263"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1263-8","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,1]]},"assertion":[{"value":"5 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics committee of Eastern Switzerland (Ethikkommission Ostschweiz, EKOS) and conducted in adherence to the Declaration of Helsinki. All patients gave written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"76"}}